

## Xenome Limited

[View the current Xenome Limited Page on BioPortfolio.com](http://www.bioportfolio.com/bioporcorporate/11089-Xenome+Limited.html)

(<http://www.bioportfolio.com/bioporcorporate/11089-Xenome+Limited.html>)

### Contact Details:

Tel:

Fax:

Email:

### Australia

Xenome aims to develop new treatments for pain, particularly intractable pain as experienced by many cancer patients, as well as other neurological conditions for which there is an unmet clinical need, e.g. stroke. Xenome has an exclusive license to a collection of molecules and related technologies discovered by the Centre for Drug Design and Development (the Centre) at the University of Queensland (now part of the Institute for Molecular Bioscience). These molecules, known as conotoxins, were isolated from the venom of several species of cone shells collected from the Great Barrier Reef and have been shown to selectively inhibit proteins known as ion-channels. Inhibition of certain ion-channels is known to control various types of pain.

Xenome intends to test naturally occurring conotoxins, as well as novel molecules, made chemically in the laboratory, for their pharmacological activity. Potentially useful molecules will then be tested in animal models for pain and other neurological conditions.

### Recent Publications by Xenome Limited:



- [chi-Conopeptide Pharmacophore Development: Toward a Novel Class of Norepinephrine Transporter Inhibitor \(Xen2174\) for Pain \(perpendicular\).](#)  
*Norepinephrine (NE) amplifies the strength of descending pain inhibition,...* 29th October, 2009  
Xenome Ltd., 120 Meiers Road, Indooroopilly, Queensland, Australia 4068.- *J Med Chem.* 2009 Nov 26;52(22):6991-7002. ([DOI Direct Link](#))
- [High-throughput synthesis of conopeptides: a safety-catch linker approach enabling disulfide formation in 96-well format.](#)  
*Conotoxins exhibit a high degree of selectivity and potency for a range of...* 27th September, 2007  
Xenome Ltd, 120 Meiers Road, Indooroopilly 4068, Australia.- *J Pept Sci.* 2007 Feb;13(2):133-41. ([DOI Direct Link](#))

- [Taxonomy of Australian Funnel-web spiders using rp-HPLC/ESI-MS profiling techniques.](#)  
*The complex nature of venom from spider species offers a unique natural...*30th June, 2006  
 Xenome Ltd, P.O. Box 6295, St Lucia, Qld 4067, Australia.- *Toxicon*. 2006 May;47(6):614-27. Epub  
 2006 Mar 22. ([DOI Direct Link](#))
- [Australian funnel-web spider venom analyzed with on-line RP-HPLC techniques.](#)  
*The complex nature of venom from spider species offers a unique natural...*25th March, 2004  
 Xenome Ltd., Indooroopilly, Queensland, Australia.- *Methods Mol Biol*. 2004;251:307-22.

**Press Releases on Xenome Limited:**

<a href="#">dazzlesmile Sues Epic Advertising and Jesse Willms</a>	25th November, 2009	dazzlesmile, llc	SALT LAKE CITY, Nov. 25 /PRNewswire/ -- dazzlesmile, llc www.dazzlesmile.com and Optimal Health Science, LLC www.optimalhealthscience.com have filed a 67-page federal lawsuit against Epic Advertising
<a href="#">China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits</a>	25th November, 2009	China Sky One Medical, Inc.	HARBIN, China, Nov. 25 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated
<a href="#">Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013</a>	25th November, 2009	Reportlinker	NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Brazil Bioethanol Market Analysis and Forecasts to 2013 http://www
<a href="#">Reportlinker Adds Transformers (Electricity) - A Global Market Review</a>	25th November, 2009	Reportlinker	NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Transformers (Electricity) - A Global Market Review http://www
<a href="#">Reportlinker Adds Intranasal Drug Delivery - US Market Trends &amp; Analysis</a>	25th November, 2009	Reportlinker	NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Intranasal Drug Delivery - US Market Trends & Analysis http://www

**Xenome Limited Patents:**



- 7507717- [Type II chi-conotoxin peptides \(noradrenaline transporter inhibitors\)](#)
- 7368432- [Conotoxin peptides](#)
- 7326682- [Conotoxin peptides](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

